Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antibiotics for pneumonia therapy

L A Mandell1

  • 1Division of Infectious Diseases, McMaster University, Hamilton, Ontario, Canada.

The Medical Clinics of North America
|September 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Un Aggiornato Profilo di Sicurezza della Moxifloxacina.

Journal of chemotherapy (Florence, Italy)·2016
Same author

Sequential antibiotic therapy: Effective cost management and patient care.

The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses·2012
Same author

Antimicrobial activity of ceftriaxone compared with cefotaxime in the presence of serum albumin.

The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses·2012
Same author

Decision analysis modelling of costs and outcomes following cefepime monotherapy in Canada.

The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses·2012
Same author

Response to "Treatment guidelines for nosocomial pneumonia: Agreeing to disagree".

The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses·2012
Same author

Methicillin-resistant staphylococcus aureus and community-acquired pneumonia: an evolving relationship.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2012

Physicians choose antimicrobials by considering in vitro activity, pharmacokinetics, and clinical trial efficacy. This article focuses on these factors, excluding adverse drug effects, which are detailed elsewhere.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Clinical Pharmacy

Background:

  • Antimicrobial selection is crucial for treating infectious diseases effectively.
  • Physicians consider multiple factors when prescribing antimicrobial agents.
  • Standard references comprehensively cover antimicrobial adverse effects.

Purpose of the Study:

  • To discuss key factors in antimicrobial selection for infectious diseases.
  • To focus on in vitro activity, pharmacokinetics, and clinical efficacy.
  • To exclude adverse drug reactions from the scope of this review.

Main Methods:

  • Review of antimicrobial selection criteria.
  • Analysis of in vitro drug activity data.
  • Evaluation of pharmacokinetic properties of antimicrobials.

Related Experiment Videos

  • Examination of clinical trial efficacy data.

    • Main Results:

    • In vitro activity, pharmacokinetics, and clinical efficacy are primary considerations for antimicrobial selection.
    • Detailed discussion of these factors is essential for optimal treatment outcomes.
    • Adverse effects, while important, are deliberately omitted to maintain focus.

    Conclusions:

    • Antimicrobial selection requires a multifaceted approach, prioritizing drug activity, pharmacokinetics, and proven efficacy.
    • Understanding these core elements is vital for physicians managing infectious diseases.
    • This article provides a focused review on critical antimicrobial selection parameters, excluding adverse effects.